Shareholder Returns

Dividend

Driven by revenue growth in North America and profit recorded from the partial transfer of the Asian business, Sumitomo Pharma's performance for FY2025 improved significantly, with core operating profit and net profit attributable to owners of the parent reaching 105.9 billion JPY and 106.9 billion JPY, respectively. Meanwhile, in pursuit of the growth strategy outlined in “Boost 2028” announced in March 2026, the Company raised funds through a public offering and other means in April 2026. The proceeds will be applied preferentially to accelerating investments centered on research and development and to restoring fiscal health. Accordingly, the Company will suspend year-end dividends for FY2025, as initially expected for the term. The Company now expects to record a core operating profit of 91.0 billion JPY for FY2026, assuming receipt of sales milestone payment from ORGOVYX®. Given the uncertain operating environment, including U.S. pricing policies, tariff measures, and rising costs associated with geopolitical conflicts, the Company has not established a forecast for interim and year-end dividends for FY2026, and it will be determined based on future performance trends and other relevant factors. The Company sincerely appreciate the kind understanding and continued support of our shareholders.

We have not split or consolidated our shares during the periods shown in the table below.

Our basic policy on profit distribution

The Company believes it important to distribute surpluses in an appropriate manner reflecting any improvement in its performance. Accordingly, a performance-linked dividend hike will be considered in addition to consistent dividend payment.

Share repurchase

No share repurchase is currently taking place.

Shareholder incentives

No shareholder incentive program is currently taking place.